

SBRI Healthcare Interim Phase 1 Report Form

This report must be received 5 working days after the end of a SBRI Healthcare's Phase 1 project's first quarter, as defined in the project's Phase 1 contract. The report should be uploaded onto SBRI Healthcare's FluidReview site, using the dedicated Task available for this report.

The aims of this document are:

- To report on the work undertaken, its success in meeting the project's objectives and to provide information that may be used by the SBRI Healthcare team in the assessment of the project's progress; and
- To explain expenditure.

Please note that the information supplied by the project in this document will be used by SBRI Healthcare to understand performance against the contracted milestones and financial management.

The report should be completed by the lead contractor, with input from any sub-contractors or project partners if appropriate. When describing technical solutions, please regard your audience as being someone familiar with the field, but not an expert in the technology. Please also explain in the report the meaning of all the acronyms used and avoid the extensive use of technical jargon.

Diagrams or pictures may be added, however be sure to keep the <u>maximum number of pages to 22</u> <u>sides of A4 in Arial 10pts minimum font size</u>.

Please note that <u>questions 9 to 17</u> relate to the commercial development and health economics of the product(s) under development. The lead contractor is asked to answer these questions in line with their expectation of the direction of the project and it is appreciated that such understanding will develop during the term of the SBRI Healthcare Phase 1 contract. As SBRI Healthcare has already received information from the project for a number of these aspects from the project's SBRI Healthcare application form, please do <u>not</u> replicate such information but instead provide further detail to highlight the project's evolving understanding in these areas.

The authors are allowed to edit the format and size of all the cells and tables in this form to better fit the text for each section. Namely, the authors are allowed to expand or reduce the size of the cells, paste new cells or extra pages, etc. However please do not exceed the maximum number of 22 pages for the complete form. Word limits are provided only as a guide to maximum expected length of responses. If a question is felt to be inapplicable to your project, please indicate this with 'N/A'.

For enquiries, please contact the SBRI Healthcare team at Health Enterprise East on Tel: 01223 928 040 or sbrienquiries@hee.co.uk

1. Details
SBRI Healthcare project title:
Registered Company Name:
Registered Address:

Town/City:
Dantas da .
Postcode:
County:
Report Author:
neport Author.
Telephone Number:
E-mail Address:
Total Contract Value: (£s)
Contract Start Date: End Date:

Milestones and key test for Phase 1 as set out in Schedule 1 of the SBRI Healthcare contract. # Milestone Date Resource Success Criteria 1

2			
3			
4			
5			
6			
7			
8			
9			
10			
V.	T4-		
кеу	Test:		

2. In reference to the milestones described above, please indicate any changes that have occurred. Include the reasons for these changes and any circumstances that assisted or hindered the progress of the project and the actions being taken to overcome them.

Milestone Actual Date Changes to milestone Outcome achieved

Delivered	(include alterations in outcome, delivery date, and/or resources)	

3. To what extent has the project to date met the key test set out in the Phase 1 contract?

(max. 300 words)

4. Have there been any changes in the management structure or personnel administering the award in the project to date?		
	(max. 300 words)	
5. Please provide a detailed summary of the outputs obtained by the		
include a description of the current iteration of the product and any a offering, along with any available data generated as part of trials/pilo		
carried out.		
	(max. 3 pages)	

6. Describe the new, innovative aspects of the work, including findings and techniques obtained by the project to date. Clearly identify where any such innovations represent an advance over the state of the art.				
	(max. 300 words)			
7. List any new Intellectual Property (IP) which has been filed or for anticipated – this could include trademarks and designs, as well as pa				
	(max. 300 words)			

8.	. Will you be applying for, or have you applied for NICE technology appraisal? An	d if so, when
		(max. 300 v
9	Please describe the product's planned route to market (distribution, sales, etc).
	(max. 30	0 words)
	10. What is the envisaged target pricing for the product(s)?	
•	(max. 30	() words)
	(max. 30)	o words)

11. What are the margins anticipated for this product?	
	(max. 300 words)
12. Please indicate the product(s) intended market launch date (eg Q1	., 2017)
	(max. 300 words)
13. Provide a description of the health economic benefits that this pro	
for the NHS, including the numbers of patients/users expected to bene savings to the NHS.	efit and potential
	(max. 300 words)
	(

	(max. 300 words)	
15. Who are you envisaging the customers for your product(s) will be?	(max. 300 words)	
16. What are your sales forecasts for the developed product(s) for years launch?	1, 2 and 3 post market	
	(max. 300 words)	
17. What are your plans for internationalisation?		
	(max. 300 words)	
		

14. Provide a brief review of the market size for this product in the NHS and beyond (EU, US, etc.), including growth rate of the market, main competitors and potential adoption

	al funding will be requir		
describe the expo	ected capital investment	and the plans to raise t	
describe the expo	ected capital investment	and the plans to raise t	(max. 300 words)
describe the expo	ected capital investment	and the plans to raise t	
describe the expo	ected capital investment	and the plans to raise t	
describe the expo	ected capital investment	and the plans to raise t	

19. The budgeted cost for your Q1, as displayed in Schedule 2 of your SBRI Healthcare contract, has been inserted into the report below. Please provide a brief description of how the SBRI Healthcare funds were spent with reference to the original budget and explain any significant variations. Confirm the final total project expenditure (£'s VAT included).

A separate financial spreadsheet template is provided to describe Quarter 1 costs in further detail.

	Budgeted Costs (£)	Actual Costs (£)	Expenditure Description	Reasons for variance between budget and actual costs
Labour Costs				
Materials Cost				
Capital Equipment				
Sub Contract Costs				
Travel & Subsistence Costs				
Indirect Costs				
Other Costs				
Total Q1 Costs (including VAT)				

20. The budgeted cost for your Q2, as displayed in Schedule 2 of your SBRI Healthcare contract, has been inserted into the report below. Please provide a brief description of how the SBRI Healthcare funds will be spent with reference to the original budget and explain any significant variations. Confirm the final total project expenditure (£'s VAT included).

A separate financial spreadsheet template is provided to describe Quarter 2 costs in further detail.

	Budgeted Costs (£)	Forecast Costs (£)	Expenditure Description	Reasons for variance between budget and forecast costs
Labour Costs				
Materials Cost				
Capital Equipment				
Sub Contract Costs				
Travel & Subsistence Costs				
Indirect Costs				
Other Costs				
Total Q2 Costs (including VAT)				

21. Describe any potential long-term collaborations/partnerships project to date and the roles these are playing in the project. This include any partnerships with NHS, social care or third sector prov	description should
	(max. 300 words)
22. Describe the trials or pilots being undertaken by the project t an indication of the number of patients/users are benefiting from these trials/pilots.	
	(max. 300 words)
23. How many clinicians/clinical teams across how many trusts/o	organisations have been
involved in developing the technology to this point?	rganisations have been
	(max. 300 words)

24. Describe how you are working with your local AHSN in respleyel of support have you received so far?	ect of this project. What	
	(max. 300 words)	
25. Has this project provided your company with any new skills o	or know-how that will enable	
growth in the forthcoming years?		
growth in the forthcoming years?	(max. 300 w	ords)
growth in the forthcoming years?	(max. 300 w	ords)
growth in the forthcoming years?	(max. 300 w	ords)
growth in the forthcoming years?	(max. 300 w	vords)
growth in the forthcoming years?	(max. 300 w	vords)
growth in the forthcoming years?	(max. 300 w	vords)
growth in the forthcoming years?	(max. 300 w	vords)
growth in the forthcoming years?	(max. 300 w	vords)
growth in the forthcoming years?	(max. 300 w	vords)
growth in the forthcoming years?	(max. 300 w	vords)
growth in the forthcoming years?	(max. 300 w	vords)

26. Has the SBRI Healthcare funding enabled you to create or safeguard jobs within your organisation? If so, how many?		
	(max. 300 words)	
27. Include details of additional funding (e.g. venture capital, equity inveinstitutional funding), leveraged as a result of the SBRI Heatlhcare award		
Please also include details of any awards or achievements directly related to date.	d to the project	
(1	max. 300 words)	

28. Provide additional information that may be pertinent. This may be in the form of text, pictures, diagrams, data, graphs that support the work. Please note this is for additional information only that could not be included in other sections.		
		(max. 600 words)
29. Declaration from the	author	
I confirm that the information given on this report is complete and correct.		
Company name:		
Signed:		Date

.....

Print name:

Company position: